MA54522A - Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire - Google Patents

Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire

Info

Publication number
MA54522A
MA54522A MA054522A MA54522A MA54522A MA 54522 A MA54522 A MA 54522A MA 054522 A MA054522 A MA 054522A MA 54522 A MA54522 A MA 54522A MA 54522 A MA54522 A MA 54522A
Authority
MA
Morocco
Prior art keywords
treatment
pharmaceutical composition
arterial hypertension
pulmonary arterial
pulmonary
Prior art date
Application number
MA054522A
Other languages
English (en)
Other versions
MA54522B1 (fr
Inventor
Dénes Csonka
Wassim Fares
Hans Hoogkamer
Koen Torfs
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69147670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA54522(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA54522A publication Critical patent/MA54522A/fr
Publication of MA54522B1 publication Critical patent/MA54522B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA54522A 2018-12-21 2019-12-20 Macitentan pour le traitement de l'hypertension artérielle pulmonaire MA54522B1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP2018086724 2018-12-21
EP2019051830 2019-01-25
EP2019060151 2019-04-18
EP2019066494 2019-06-21
EP2019067186 2019-06-27
PCT/EP2019/086754 WO2020128017A1 (fr) 2018-12-21 2019-12-20 Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire
EP19832954.2A EP3897646B1 (fr) 2018-12-21 2019-12-20 Macitentan pour le traitement de l'hypertension artérielle pulmonaire

Publications (2)

Publication Number Publication Date
MA54522A true MA54522A (fr) 2022-03-23
MA54522B1 MA54522B1 (fr) 2024-07-31

Family

ID=69147670

Family Applications (1)

Application Number Title Priority Date Filing Date
MA54522A MA54522B1 (fr) 2018-12-21 2019-12-20 Macitentan pour le traitement de l'hypertension artérielle pulmonaire

Country Status (30)

Country Link
US (3) US11234980B2 (fr)
EP (1) EP3897646B1 (fr)
JP (2) JP2022512493A (fr)
KR (1) KR20210109558A (fr)
CN (1) CN113194953A (fr)
AU (1) AU2019410727B2 (fr)
BR (1) BR112021011999A2 (fr)
CA (1) CA3123990A1 (fr)
CL (1) CL2021001636A1 (fr)
CO (1) CO2021007186A2 (fr)
DK (1) DK3897646T3 (fr)
ES (1) ES2983314T3 (fr)
FI (1) FI3897646T3 (fr)
HR (1) HRP20240875T1 (fr)
HU (1) HUE067126T2 (fr)
IL (1) IL284136A (fr)
JO (1) JOP20210153B1 (fr)
LT (1) LT3897646T (fr)
MA (1) MA54522B1 (fr)
MX (1) MX2021007455A (fr)
PH (1) PH12021551371A1 (fr)
PL (1) PL3897646T3 (fr)
PT (1) PT3897646T (fr)
RS (1) RS65689B1 (fr)
SG (1) SG11202105098VA (fr)
SI (1) SI3897646T1 (fr)
SM (1) SMT202400274T1 (fr)
TW (1) TWI841649B (fr)
WO (1) WO2020128017A1 (fr)
ZA (1) ZA202105111B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY199557A (en) 2017-02-27 2023-11-07 Idorsia Pharmaceuticals Ltd Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
CA3116166C (fr) * 2018-10-12 2026-02-17 Sanotize Research And Development Corp. Compositions a degagement de gaz et systemes de recipient et de distribution
DK3897646T3 (da) 2018-12-21 2024-07-01 Actelion Pharmaceuticals Ltd Macitentan til behandling af pulmonal arteriel hypertension
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
EP4065119B1 (fr) * 2019-11-29 2024-09-04 Actelion Pharmaceuticals Ltd Traitement initial par triple combinaison avec macitentan, tadalafil et selexipag pour traiter l'hypertension artérielle pulmonaire
EP4297754A1 (fr) * 2021-02-26 2024-01-03 Actelion Pharmaceuticals Ltd Procédés de traitement de l'hypertension pulmonaire chez des patients ayant une implantation de dispositif d'assistance ventriculaire gauche

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1345920E (pt) 2000-12-18 2006-08-31 Actelion Pharmaceuticals Ltd Novas sulfonamidas e sua utilizacao como antagonistas dos receptores de endotelina
WO2007031933A2 (fr) * 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Composition pharmaceutique stable a pyrimidine-sulfamide
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
MX350011B (es) 2008-08-13 2017-08-22 Actelion Pharmaceuticals Ltd Composiciones terapeuticas que contienen macitentan.
AU2017357759A1 (en) * 2016-11-10 2019-06-06 Arena Pharmaceuticals, Inc. Methods of treating PAH with combinations of ralinepag and other agents
WO2018153925A1 (fr) * 2017-02-22 2018-08-30 Amneal Pharmaceuticals Company Gmbh Compositions pharmaceutiques stables comprenant du macitentan
MY199557A (en) 2017-02-27 2023-11-07 Idorsia Pharmaceuticals Ltd Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
DK3897646T3 (da) 2018-12-21 2024-07-01 Actelion Pharmaceuticals Ltd Macitentan til behandling af pulmonal arteriel hypertension
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
TW202103703A (zh) 2019-04-05 2021-02-01 瑞士商艾克泰聯製藥有限公司 用於治療門脈肺高血壓之方法
EP4065081A1 (fr) 2019-11-26 2022-10-05 Actelion Pharmaceuticals Ltd Composition pharmaceutique pour le traitement d'une maladie vasculaire pulmonaire et/ou d'un dysfonctionnement cardiaque chez des patients ayant subi une intervention de fontan

Also Published As

Publication number Publication date
DK3897646T3 (da) 2024-07-01
JP2022512493A (ja) 2022-02-04
CN113194953A (zh) 2021-07-30
PT3897646T (pt) 2024-07-08
AU2019410727B2 (en) 2025-05-08
SMT202400274T1 (it) 2024-09-16
HRP20240875T1 (hr) 2024-10-11
ES2983314T3 (es) 2024-10-22
JP2024105450A (ja) 2024-08-06
TW202034923A (zh) 2020-10-01
ZA202105111B (en) 2023-03-29
FI3897646T3 (fi) 2024-06-26
RS65689B1 (sr) 2024-07-31
EP3897646A1 (fr) 2021-10-27
BR112021011999A2 (pt) 2021-09-08
CO2021007186A2 (es) 2021-06-10
US20210196715A1 (en) 2021-07-01
SG11202105098VA (en) 2021-06-29
KR20210109558A (ko) 2021-09-06
CL2021001636A1 (es) 2022-02-18
US11464777B2 (en) 2022-10-11
EP3897646B1 (fr) 2024-05-22
SI3897646T1 (sl) 2024-08-30
TWI841649B (zh) 2024-05-11
PL3897646T3 (pl) 2024-07-22
US20220096476A1 (en) 2022-03-31
US11234980B2 (en) 2022-02-01
JOP20210153A1 (ar) 2023-01-30
JOP20210153B1 (ar) 2024-12-22
MX2021007455A (es) 2021-08-05
IL284136A (en) 2021-08-31
LT3897646T (lt) 2024-07-10
WO2020128017A1 (fr) 2020-06-25
PH12021551371A1 (en) 2021-11-29
MA54522B1 (fr) 2024-07-31
AU2019410727A1 (en) 2021-08-12
HUE067126T2 (hu) 2024-10-28
US20230020241A1 (en) 2023-01-19
CA3123990A1 (fr) 2020-06-25

Similar Documents

Publication Publication Date Title
MA54522A (fr) Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
EP3893940A4 (fr) Polythérapie pour le traitement de la dystrophie musculaire
MA51916A (fr) Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide
EP3790867A4 (fr) Inhibiteurs de kdm1a pour le traitement d'une maladie
EP3704108A4 (fr) Composés et compositions pour le traitement de troubles hématologiques
EP3645039A4 (fr) Utilisation d'anticorps anti-fam19a5 pour le traitement de la fibrose
EP3496662A4 (fr) Protéine dérivée de la soie pour le traitement d'une inflammation
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3810091A4 (fr) Méthodes et compositions pour le traitement de l'hypertension pulmonaire
EP3541379A4 (fr) Compositions pour le traitement de l'hypertension
EP3773221A4 (fr) Traitement pour l'hydrocéphalie
EP3716966A4 (fr) Compositions d'alpha-cétoacides pour le traitement de l'hypoalbuminémie
MA55490A (fr) Mutéine de lipocaline pour le traitement de l'asthme
EP3877402A4 (fr) Traitement combiné pour l'hypertension résistante
MA55982A (fr) Composition pharmaceutique pour le traitement de tumeurs
EP3758716A4 (fr) Formulations pour le traitement du reflux acide comprenant de l'alginate de sodium
EP3883552A4 (fr) Composés cyanoaryl-aniline pour le traitement d'affections de la peau
EP4181915A4 (fr) Compositions pour le traitement de l'obésité
EP3996729C0 (fr) Composition pour la prévention ou le traitement de la dépression ou de l'anxiété
EP3826633A4 (fr) Compositions pour le traitement de l'hypertension
EP4052694A4 (fr) Composition de gouttes oculaires pour la prévention ou le traitement d'une maladie oculaire
EP3880244A4 (fr) Compositions immunogènes pour le traitement de l'hépatite b
EP4340881A4 (fr) Anticorps pour le traitement d'alpha-synucléinopathies
EP3810647A4 (fr) Méthodes et compositions pour le traitement de l'hémophilie